PIPORTIL L4 SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

PIPOTIAZINE PALMITATE

Pieejams no:

SANOFI-AVENTIS CANADA INC

ATĶ kods:

N05AC04

SNN (starptautisko nepatentēto nosaukumu):

PIPOTIAZINE

Deva:

50MG

Zāļu forma:

SOLUTION

Kompozīcija:

PIPOTIAZINE PALMITATE 50MG

Ievadīšanas:

INTRAMUSCULAR

Vienības iepakojumā:

5X2ML

Receptes veids:

Prescription

Ārstniecības joma:

PHENOTHIAZINES

Produktu pārskats:

Active ingredient group (AIG) number: 0112633001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2017-03-30

Produkta apraksts

1
PRODUCT MONOGRAPH
PR
PIPORTIL
® L
4
(PIPOTIAZINE PALMITATE INJECTION)
25 MG/ML AND 50 MG/ML
ANTIPSYCHOTIC AGENT
sanofi-aventis Canada Inc.
2150 St. Elzear Blvd. West
Laval, Quebec H7L 4A8
Date of Revision:
OCTOBER 31, 2011
Submission Control No.: 149573
s-a Version 6.0 dated
2
NAME OF DRUG
PR
PIPORTIL
® L
4
(PIPOTIAZINE PALMITATE INJECTION)
THERAPEUTIC CLASSIFICATION
ANTIPSYCHOTIC AGENT
ACTION
Piportil
®
L
4
(pipotiazine palmitate) is the palmitic ester of pipotiazine, a
piperidine
phenothiazine with antipsychotic properties and weak sedative
activity. The esterification
of pipotiazine is responsible for its prolonged duration of action.
The onset of action
appears usually within the first 2 to 3 days after injection and the
effects of the drug on
psychotic symptoms are significant within one week. Improvement in
symptomatology
lasts from 3 to 6 weeks, but adequate control may frequently be
maintained with one
injection every 4 weeks. However, in view of the variations in
individual response,
careful supervision is required throughout treatment.
Piportil
L
4
has actions similar to those of other phenothiazines. Among the
different
phenothiazine derivatives, Piportil
L
4
appears to be less sedating and to have a weak
propensity for causing hypotension or potentiating the effects of CNS
depressants and
anesthetics. However, it produces a high incidence of extrapyramidal
reactions.
_ _
INDICATIONS
Piportil L
4
(pipotiazine palmitate) is indicated in the maintenance treatment of
chronic
non-agitated schizophrenic patients.
CONTRAINDICATIONS
Piportil
L
4
(pipotiazine
palmitate)
should
not
be
administered
in
the
presence
of
circulatory collapse, altered states of consciousness or comatose
states, particularly when
these are due to intoxication with central depressant drugs (alcohol,
hypnotics, narcotics,
etc.). It is contraindicated in severely depressed patients, in the
presence of blood
dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or
in patients with
severe
cardiovascular
disorders
or
a
hist